Heron Therapeutics, Inc.
HRTXNASDAQHealthcare● Active
$0.45
$-0.00(-0.26%)
Market Cap$71452015
P/E Ratio—
52W High$2.3
52W Low$0.42
Heron Therapeutics, Inc. (HRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HRTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.15B | $0.14B | $0.13B | $0.11B | $0.09B |
| Cost of Revenue | $0.04B | $0.04B | $0.07B | $0.05B | $0.05B |
| Gross Profit | $0.11B | $0.11B | $0.06B | $0.05B | $0.04B |
| Gross Margin %(computed) | 73.31% | 73.21% | 48.75% | 49.04% | 46.70% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.02B | $0.04B | $0.08B | $0.13B |
| G&A Expenses | $0.05B | $0.05B | $0.06B | $0.06B | $0.04B |
| Total Operating Expenses | $0.12B | $0.12B | $0.17B | $0.23B | $0.26B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.11B) | ($0.17B) | ($0.22B) |
| Operating Margin %(computed) | -1.64% | -7.99% | -87.07% | -162.21% | -252.27% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.01B) | ($0.11B) | ($0.18B) | ($0.22B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.01B) | ($0.11B) | ($0.18B) | ($0.22B) |
| Net Margin %(computed) | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
| Wtd Avg Shares | 0.17B | 0.15B | 0.14B | 0.11B | 0.10B |
| EBITDA | ($0.02B) | ($0.01B) | ($0.10B) | ($0.18B) | ($0.22B) |
| EBITDA Margin %(computed) | -11.54% | -3.50% | -81.70% | -164.07% | -249.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Heron Therapeutics, Inc. data
About Heron Therapeutics, Inc. (HRTX) Income Statement
Heron Therapeutics, Inc. (HRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HRTX reported revenue of $0.15B, gross profit of $0.11B (gross margin 73.31%), and net income of ($0.02B) — a net profit margin of -13.04%.
Frequently asked questions
HRTX · 4 questionsHeron Therapeutics, Inc. (HRTX) reported revenue of $0.15B for 2025, up 7.4% year-over-year.
HRTX revenueHRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09